A retrospective trial to study the response benefit by switching therapy to a switching therapy to a second generation tyrosine kinase inhibitor in patients with chronic myeloid leukemia.
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2015
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 18 Dec 2015 New trial record